IL308074A - Preparations containing N,N-DIMETHYLTRYPTAMINE and their uses - Google Patents

Preparations containing N,N-DIMETHYLTRYPTAMINE and their uses

Info

Publication number
IL308074A
IL308074A IL308074A IL30807423A IL308074A IL 308074 A IL308074 A IL 308074A IL 308074 A IL308074 A IL 308074A IL 30807423 A IL30807423 A IL 30807423A IL 308074 A IL308074 A IL 308074A
Authority
IL
Israel
Prior art keywords
dmt
minutes
composition according
disorder
administration
Prior art date
Application number
IL308074A
Other languages
English (en)
Hebrew (he)
Inventor
Glenn Short
Srinivas Rao
Original Assignee
Atai Therapeutics Inc
Glenn Short
Srinivas Rao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atai Therapeutics Inc, Glenn Short, Srinivas Rao filed Critical Atai Therapeutics Inc
Publication of IL308074A publication Critical patent/IL308074A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL308074A 2021-04-26 2022-04-26 Preparations containing N,N-DIMETHYLTRYPTAMINE and their uses IL308074A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163179679P 2021-04-26 2021-04-26
PCT/US2022/026396 WO2022232179A1 (en) 2021-04-26 2022-04-26 Novel n,n-dimethyltryptamine compositions and methods

Publications (1)

Publication Number Publication Date
IL308074A true IL308074A (en) 2023-12-01

Family

ID=83694712

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308074A IL308074A (en) 2021-04-26 2022-04-26 Preparations containing N,N-DIMETHYLTRYPTAMINE and their uses

Country Status (12)

Country Link
US (1) US11602521B2 (cg-RX-API-DMAC7.html)
EP (1) EP4329879A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024517738A (cg-RX-API-DMAC7.html)
KR (1) KR20240000516A (cg-RX-API-DMAC7.html)
CN (1) CN117320711A (cg-RX-API-DMAC7.html)
AU (1) AU2022267240A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023022195A2 (cg-RX-API-DMAC7.html)
CA (1) CA3216889A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003191A1 (cg-RX-API-DMAC7.html)
IL (1) IL308074A (cg-RX-API-DMAC7.html)
MX (1) MX2023012651A (cg-RX-API-DMAC7.html)
WO (1) WO2022232179A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3753923A1 (en) 2019-06-19 2020-12-23 GH Research Limited Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent
EP3868364A1 (en) 2020-02-24 2021-08-25 GH Research Limited Aerosol comprising 5-methoxy-n,n-dimethyltryptamine
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
KR20240013170A (ko) 2021-05-25 2024-01-30 아타이 테라퓨틱스, 인크. 신규 n,n-디메틸트립타민 염 및 결정질 염 형태
IL309210A (en) 2021-06-09 2024-02-01 Atai Therapeutics Inc Parent drugs and conjugates of dimethyltryptamine
CA3238440A1 (en) 2021-12-30 2023-07-06 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
KR20250005182A (ko) * 2022-03-27 2025-01-09 지에이치 리서치 아일랜드 리미티드 인지기능 장애 치료를 위한 5-메톡시-n,n-다이메틸트립타민
EP4608395A2 (en) * 2022-10-26 2025-09-03 ATAI Therapeutics, Inc. N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof
DK202330319A1 (en) * 2023-11-07 2025-05-27 Fertin Pharma As An adhesive oral disc for sustained release of cannabinoids
US20240325351A1 (en) 2023-03-31 2024-10-03 Cybin UK Ltd. Method of administration
EP4773958A1 (en) * 2023-09-08 2026-07-15 ATAI Therapeutics, Inc. Parenteral formulations for n,n-dimethyltryptamine (dmt) and dmt analogs, methods of making, and methods of use thereof
EP4788322A1 (en) * 2023-10-02 2026-08-12 ATAI Therapeutics, Inc. N-n-dimethyltryptamine (dmt) and dmt analog oral transmucosal film compositions, methods of making, and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60215685A (ja) * 1984-04-11 1985-10-29 Takeda Chem Ind Ltd 2’−デオキシアリステロマイシン誘導体およびその用途
US20220079881A1 (en) 2016-03-03 2022-03-17 Ctt Pharma Inc. Orally Administrable Composition
US11723894B2 (en) * 2017-10-26 2023-08-15 Terran Biosciences, Inc. Combination product for the treatment of neurological and/or psychiatric disorders
DK3927338T3 (da) * 2019-02-22 2025-01-06 Gh Res Ireland Limited Sammensætninger omfattende 5-methoxy-n,n-dimethyltryptamin (5-meo-dmt) til anvendelse i behandling af mentale lidelser
HUE066828T2 (hu) 2019-02-22 2024-09-28 Gh Res Ireland Limited 5-Metoxi-N,N-Dimetiltriptamin (5-Meo-Dmt) súlyos depressziós rendellenesség kezelésére
KR102946120B1 (ko) * 2019-02-27 2026-03-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클
WO2020176597A1 (en) * 2019-02-27 2020-09-03 The Regents Of The University Of California N-substituted indoles and other heterocycles for treating brain disorders
GB201907871D0 (en) * 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
WO2021003467A1 (en) * 2019-07-04 2021-01-07 Sw Holdings, Inc. Metered dosing compositions and methods of use of psychedelic compounds
US20210015738A1 (en) * 2019-07-17 2021-01-21 Concept Matrix Solutions Oral dissolvable film containing psychedelic compound
US20210023052A1 (en) * 2019-07-23 2021-01-28 Caamtech Llc Compositions containing toad secretion compounds
WO2021041407A1 (en) * 2019-08-25 2021-03-04 Caamtech Llc Alkyl quarternary ammonium tryptamines and their therapeutic uses
CN115297851A (zh) * 2019-12-31 2022-11-04 Tf科技企业 口溶膜及其生产和使用方法
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
EP4167992A1 (en) * 2020-06-22 2023-04-26 University of Zürich Compositions and kits of parts comprising n,n-dimethyltryptamine and harmine and their use in therapy
CA3188263A1 (en) * 2020-08-05 2022-02-10 Matthias Emanuel LIECHTI Intravenous dmt administration method for dmt-assisted psychotherapy
CA3192617A1 (en) 2020-09-20 2022-03-24 Matthew BAGGOTT Advantageous tryptamine compositions for mental disorders or enhancement
KR20240013170A (ko) * 2021-05-25 2024-01-30 아타이 테라퓨틱스, 인크. 신규 n,n-디메틸트립타민 염 및 결정질 염 형태

Also Published As

Publication number Publication date
JP2024517738A (ja) 2024-04-23
EP4329879A4 (en) 2025-04-09
MX2023012651A (es) 2023-11-06
AU2022267240A1 (en) 2023-11-23
US20220339139A1 (en) 2022-10-27
BR112023022195A2 (pt) 2024-01-16
CA3216889A1 (en) 2022-11-03
KR20240000516A (ko) 2024-01-02
WO2022232179A9 (en) 2023-07-13
EP4329879A1 (en) 2024-03-06
US11602521B2 (en) 2023-03-14
CN117320711A (zh) 2023-12-29
CL2023003191A1 (es) 2024-04-01
WO2022232179A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
US11602521B2 (en) N,N-dimethyltryptamine compositions and methods
JP7492548B2 (ja) アルコール使用障害の処置のための組成物、装置、及び、方法
US20260116853A1 (en) New n,n-dimethyltryptamine salts and crystalline salt forms
JP6112867B2 (ja) サキシトキシン誘導体での触覚の喪失の処置
KR20130135296A (ko) 베포타스틴 조성물
PL207845B1 (pl) Spray donosowy do dostarczania kompozycji farmaceutycznej zawierającej fentanyl i zastosowanie soli fentanylu do wytwarzania środka leczniczego
CA3043028A1 (en) Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions
AU2012275113A1 (en) Alcaftadine for use in the treatment of urticaria
CN106413708A (zh) Nmda受体拮抗剂的医药用途及其药物组合物
WO2025170990A1 (en) Controlled transmucosal release of dmt in combination with a monoamine oxidase inhibitor
JP2024019731A (ja) ベタヒスチンを含む鼻腔内組成物
WO2025054397A9 (en) Parenteral formulations for n,n-dimethyltryptamine (dmt) and dmt analogs, methods of making, and methods of use thereof
WO2025024637A1 (en) Compositions for limiting sympathomimetic effects of psychedelic therapeutics
WO2025076151A1 (en) N-n-dimethyltryptamine (dmt) and dmt analog oral transmucosal film compositions, methods of making, and methods of use thereof
KR20260013222A (ko) 트립타민 유도체를 함유하는 제제 및 그의 용도
WO2024092106A2 (en) N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof
JP2024531685A (ja) 神経障害の処置
WO2023108074A1 (en) Novel salvinorin compositions
HK40092206A (en) Intranasal epinephrine formulations and methods for the treatment of disease